GlassScriptPhysician profile
Alison D Allor
NPI 1184811036
$30,143.37
in general payments reported to CMS, 2019-2025
24 companies · $887 in 2025
The $887 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $5,795 · 2022: $6,958 · 2023: $7,051 · 2024: $9,453 · 2025: $887.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $11K · Travel and Lodging: $3,983 · Food and Beverage: $2,841 · Education: $66.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $10,500.00 |
| Travel and Lodging | $3,982.66 |
| Food and Beverage | $2,841.14 |
| Education | $66.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $26,697.74 | 2021-2024 | Velphoro, Korsuva |
| Vifor Pharma, INC. | $453.03 | 2021-2024 | Veltassa, Korsuva |
| Astrazeneca Pharmaceuticals LP | $354.56 | 2022-2025 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $324.64 | 2023-2025 | |
| Travere Therapeutics, INC. | $316.69 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $281.91 | 2024-2025 | |
| Aurinia Pharma U.S., INC. | $272.32 | 2021-2025 | Lupkynis |
| Ardelyx, INC. | $209.81 | 2024-2025 | Xphozah 30 Mg, Ibsrela |
| Novo Nordisk INC | $195.20 | 2022-2025 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $187.92 | 2023-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $148.20 | 2023-2025 | Jynarque |
| Opko Pharmaceuticals, LLC | $137.49 | 2021-2025 | Rayaldee |
| Amgen INC. | $119.48 | 2021-2022 | |
| Calliditas Therapeutics US INC. | $108.10 | 2022-2024 | Tarpeyo |
| Ani Pharmaceuticals, INC. | $82.09 | 2023-2025 | Purified Cortrophin Gel |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $43.51 | 2022 | |
| Glaxosmithkline, LLC. | $43.18 | 2021-2025 | Benlysta |
| Genzyme Corporation | $40.25 | 2021-2023 | |
| Mallinckrodt Hospital Products INC. | $33.51 | 2024-2025 | Terlivaz, Acthar |
| Alexion Pharmaceuticals, INC. | $31.43 | 2025 | Ultomiris |
| Alnylam Pharmaceuticals INC. | $20.44 | 2024 | Oxlumo |
| Apellis Pharmaceuticals, INC. | $15.16 | 2025 | |
| Chiesi USA, INC. | $14.33 | 2025 | Elfabrio |
| Nxstage Medical, INC. | $12.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alison Allor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.